Product Description
Fostamatinib is used to treat thrombocytopenia (less than normal number of platelets) in adults with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) who were not helped with another treatment. Fostamatinib is in a class of medications called kinase inhibitors. It works by reducing platelet destruction. (Sourced from: https://medlineplus.gov/druginfo/meds/a618025.html)
Mechanisms of Action: SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Slovakia | Spain | Sweden | United Kingdom | United States
Approved Indications: Thrombocytopenia | Purpura, Thrombocytopenic, Idiopathic
Known Adverse Events: Hypertension | Abdominal Pain | Chest Pain | Dizziness | Pain Unspecified | Neutropenia | Contraception | Pregnancy Outcomes | Pregnancy, Abdominal | Diarrhea
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Mexico, Netherlands, Norway, Romania, Russia, Serbia, Spain, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Anemia, Hemolytic, Autoimmune|COVID-19|Pneumonia|Purpura, Thrombocytopenic, Idiopathic|Severe Acute Respiratory Syndrome
Phase 2: Acute Lung Injury|Acute Respiratory Distress Syndrome|Hidradenitis Suppurativa|Inflammation|Respiratory Distress Syndrome, Newborn
Phase 1: Adenocarcinoma|Bronchiolitis Obliterans|Graft vs Host Disease|Ovarian Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Pro00113327 | P1 |
Not yet recruiting |
Bronchiolitis Obliterans|Graft vs Host Disease |
2029-01-01 |
|
| NCT06639724 | P1 |
Not yet recruiting |
Adenocarcinoma|Pancreatic Ductal Carcinoma|Pancreatic Cancer |
2027-06-01 |
|
| FOSTA-ARDS | P2 |
Not yet recruiting |
Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury |
2025-08-31 |
|
| C-935788-058 | P3 |
Enrolling by invitation |
Anemia, Hemolytic, Autoimmune |
2024-04-01 |
79% |